Clinical Study
Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
Table 5
Main trials on adjuvant treatments comparing chemoradiotherapy with radiotherapy alone after primary surgery.
| Author (year) | Patients | Compared arm | Median follow-up (months) | Outcome |
|
Bachaud et al. 1996# [10] | 83# | CP + RT vs. RT alone# | 60.0# | 2 y DFS rate, 68% vs. 44% ()# | 2 y OS rate, 72% vs. 46% ()# |
|
Salama et al. 2007 [11] | 114 | Mito + Bleo + RT vs. RT alone | 32.2 | 2 y DFS rate, 76% vs. 60% () | 2 y OS rate, 74% vs. 64% () |
|
Cooper et al. 2004 [1] | 459 | CP + RT vs. RT alone | 45.9 | 2 y DFS rate, 54% v. 45% () | 2 y OS rate, 64% vs. 57% () |
|
Bernier et al. 2004 [2] | 334 | CP + RT vs. RT alone | 60.0 | 5 y PFS rate, 47% vs. 36% () | 5 y OS rate, 53% vs. 40% () |
| Current study | 126 | CP + uracil-Tegafur + RT | 30.0 | 2 y DFS rate, 70.9% | 2 y OS rate, 79.5% |
|
|
Mito: mitomycin C; Bleo: bleomycin; RT: radiotherapy; CP: cisplatin; LRC: locoregional control; DFS: disease-free survival; OS: overall survival.
|